Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Pablo E. Pérgola et al.|The Lancet|2019Cited by 609
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital AdmissionPeter S. Hamblin, Leon A. Bach, Rosemary Wong et al.|The Journal of Clinical Endocrinology & Metabolism|2019Cited by 122
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E. Pratley, Kenneth W. Mahaffey, Katherine R. Tuttle et al.|Journal of the American College of Cardiology|2024Cited by 107
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathySally A. Penfold, Josephine M. Forbes, Melinda T. Coughlan et al.|Kidney International|2010Cited by 78
Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial HomeostasisMelinda T. Coughlan, Josephine M. Forbes, Gavin C. Higgins et al.|Diabetes|2016Cited by 57